Abstract:Recent advances in cancer treatment have emerged from new immunotherapies targeting T-cell inhibitory receptors, including cytotoxic T-lymphocyte associated antigen (CTLA)-4 and programmed cell death (PD)-1. In this context, anti-CTLA-4 and anti-PD-1 monoclonal antibodies have demonstrated survival benefits in numerous cancers, including melanoma and non-small-cell lung carcinoma. PD-1-expressing CD8+ T lymphocytes appear to play a major role in the response to these immune checkpoint inhibitors (ICI). Cytotoxic T lymphocytes (CTL) eliminate malignant cells through recognition by the T-cell receptor (TCR) of specific antigenic peptides presented on the surface of cancer cells by major histocompatibility complex class I/beta-2-microglobulin complexes, and through killing of target cells, mainly by releasing the content of secretory lysosomes containing perforin and granzyme B. T-cell adhesion molecules and, in particular, lymphocyte-function-associated antigen-1 and CD103 integrins, and their cognate ligands, respectively, intercellular adhesion molecule 1 and E-cadherin, on target cells, are involved in strengthening the interaction between CTL and tumor cells. Tumor-specific CTL have been isolated from tumor-infiltrating lymphocytes and peripheral blood lymphocytes (PBL) of patients with varied cancers. TCRβ-chain gene usage indicated that CTL identified in vitro selectively expanded in vivo at the tumor site compared to autologous PBL. Moreover, functional studies indicated that these CTL mediate human leukocyte antigen class I-restricted cytotoxic activity toward autologous tumor cells. Several of them recognize truly tumor-specific antigens encoded by mutated genes, also known as neoantigens, which likely play a key role in antitumor CD8 T-cell immunity. Accordingly, it has been shown that the presence of T lymphocytes directed toward tumor neoantigens is associated with patient response to immunotherapies, including ICI, adoptive cell transfer, and dendritic cell-based vaccines. These tumor-specific mutation-derived antigens open up new perspectives for development of effective second-generation therapeutic cancer vaccines.

Focusing on CD8+ T-cell phenotypes: improving solid tumor therapy

Genetically engineered T cells for cancer immunotherapy

CD8+ T cell-based cancer immunotherapy

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy

Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy

CX3CR1+CD8+ T cells: Key players in antitumor immunity

Strategies to reinvigorate exhausted CD8+ T cells in tumor microenvironment

Improving the ability of CAR-T cells to hit solid tumors: Challenges and strategies

Exhausted CD8+T Cells in the Tumor Immune Microenvironment: New Pathways to Therapy

Reinvigorating Exhausted CD8+ Cytotoxic T Lymphocytes in the Tumor Microenvironment and Current Strategies in Cancer Immunotherapy

Programming CAR T cells to enhance anti-tumor efficacy through remodeling of the immune system

Toward a comprehensive solution for treating solid tumors using T-cell receptor therapy: A review

Regulation of CD8+ T cells by lipid metabolism in cancer progression

How does TCR-T cell therapy exhibit a superior anti-tumor efficacy

TCR-T Immunotherapy: The Challenges and Solutions

Progresses of T-cell-engaging bispecific antibodies in treatment of solid tumors

Phenotypic and spatial heterogeneity of CD8+ tumour infiltrating lymphocytes

CD8+T Cell-Dependent Remodeling of the Tumor Microenvironment Overcomes Chemoresistance

Metabolic reprogramming in the tumor microenvironment: unleashing T cell stemness for enhanced cancer immunotherapy

Novel Strategies to Improve CAR-T Cell Efficacy by Targeting the Solid Tumor Microenvironment

Rationally designed approaches to augment CAR-T therapy for solid tumor treatment